UK pharma companies told to make fewer drugs in draft net zero guidelines
Suggestion among an array of green proposals British companies urged to consider
Suggestion among an array of green proposals British companies urged to consider
Thousands of retirement plans in chaos as new managers scrap ‘discretionary’ benefit
Questor share tip: Novartis can also boast excellent cash generation that has allowed it to raise its dividend for 27 years
Shares in Exscientia plunge almost a fifth following termination of founder's employment
The government is granting necessary powers to pharmacies – but most are already struggling to cope
From late January, pharmacists will be allowed to treat new conditions, saving patients hours on the phone - and allowing GPs more time
Sufferers will be injected with new drug twice-yearly to reduce inflammation
At least its final guest editor of the festive season had something to say, as big Pharma CEO Emma Walmsley discussed the future of the NHS
You may not know Novo Nordisk but, under Lars Fruergaard Jørgensen’s leadership, their products have become household names
Continent’s inability to produce own vaccines could be solved by rollout of portable high-tech labs housed in shipping containers
London’s ailing stock market needs more than the return of a high street pharmacy
Questor Wealth Preserver: as one of our holdings looks likely to be taken over, we are replacing it with a high-quality pharmaceutical stock
Plans to go public could provide much-needed boost for ailing stock market
Anglo-Swedish drug giant is fighting a multi-million pound legal case in the High Court
Novo Nordisk aims to treat more people who currently cannot access its Wegovy jabs
Empagliflozin, which reduces the need for dialysis or transplants by almost a third, will be available on NHS from the start of next year
Three widows share their struggles to have the Covid jab recorded as the official cause of death of their husbands
Novo Nordisk is struggling to meet a surge in demand for its treatments
Pharmaceutical giant strikes deal to develop new drugs after admitting it is behind rivals
Health service is willing to pay half as much on new drugs to give you ‘perfect health’
Sales of Novo Nordisk's obesity treatments grew 36pc in the first nine months of the year
Company’s chief executive and three other senior employees given two-year prison sentences and fined £52,000
Science is moving so quickly that we aren’t taking the time to consider what this holy grail could actually be doing